Modulation of proteinase receptor 2: a novel target for cancer immunotherapy

Treatments empowering patient’s own immune system (immunotherapy) have revolutionized cancer treatment this last decade, showing substantial clinical activity in different tumor types. However, 60% of cancer patients still fail to respond to immunotherapy and other standard of care. Our laboratory recently identified the proteinase receptor 2as a new target to overcome immunotherapy resistance. We propose to investigate the therapeutic potential of this receptor for cancer immunotherapy. We will evaluate its role in the response to immunotherapies and gain a better understanding of the mechanisms involved. This project has the potential to lead to the rapid clinical development of a new immunotherapy and to provide a significant clinical benefit to cancer patients resistant to current cancer treatment.

Faculty Supervisor:

John Stagg

Student:

Partner:

Domain Therapeutics NA Inc

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

Université de Montréal

Program: